14 results about "Cell soma" patented technology

The application relates to a G-quadruplex RNA fluorescent ligand and a preparation method and application thereof, a structure formula of the G-quadruplex RNA fluorescent ligand is shown in the following formula: the compound can be specifically targeted and can be subjected to fluorescent imaging in a solution system and a cell system, a high-throughput fluorescent screening method is established in the solution and the cell system, and an organic small-molecule compound with strong binding capacity to G-quadruplex RNA can be effectively identified and screened from a small-molecule drug library; the screening result of the method is high in accuracy, the affinity and biological activity of a candidate compound can be quickly determined by evaluating the change of a fluorescent signal, and therefore the research and development process of an antitumor drug is accelerated; and the application belongs to the field of biological medicines.

Methods of treating diseases associated with pathologic neuronal cells are provided. Accordingly, there is provided a method of treating a disease associated with pathologic neuronal cells characterized by aberrant excitability comprising: (a) administering into a first neural region of the subject a therapeutically effective amount of a polynucleotide encoding a bistable type II opsin attached to a heterologous ER export signal and / or membrane trafficking signal which enables trafficking of said bistable type II opsin to axon and / or dendrite terminals, wherein said first neural region comprises cell bodies of said pathologic neuronal cells; and (b) exposing a second neural region of said subject to light in a wavelength that activates said bistable type II opsin, wherein said second neural region comprises axon or dendrite terminals of said pathologic neuronal cells associated with a symptom of said disease, and wherein said first neural region and said second neural region are distinct.

The application discloses a Turn-Off type cell in-vivo tracing probe and a preparation method and application thereof, and the probe structure is composed of three parts, including a membrane anchoring part, an enzyme specificity response part and a fluorescent group. The probe can mark cells through the hydrophobic tail chain of the membrane anchoring part, at this time, the fluorescent group part emits near-infrared fluorescence, and shows a Turn state. When the adoptive cells are apoptotic in the body, the probe falls off from the cells. The free probe falling off is phagocytosed by macrophages in the body, in the intracellular macrophages, the enzyme specificity response part in the probe structure responds to enzyme bond breaking, the fluorescent group is dissociated, does not emit light, and shows an Off state. Therefore, the fluorescent probe can not only trace the in-vivo living cells and monitor the death and life of the cells in the body, but also can effectively overcome the fluorescent "pollution" phenomenon caused by the persistent existence of the fluorescent of the free probe falling off, and provides a new visual tool for monitoring the in-vivo fate of the living cell drugs.

The application discloses application of ostruthin in enhancing CAR-T cell anti-tumor function, belongs to the technical field of biological medicine, and the ostruthin can promote cell proliferation, inhibit cell exhaustion, promote the secretion of cytokines related to killing cancer cells, and further enhance the anti-tumor function of CAR-T cells in vivo and in vitro as a cell enhancer of CAR-T cells; experimental results show that when ostruthin is combined with CAR-T cells for anti-tumor treatment, compared with ostruthin or CAR-T cells alone, the combination of the two can significantly inhibit the growth of solid tumors. The application provides a new technical means for improving the tumor treatment effect of CAR-T cell immunotherapy.

The application provides a method for enhancing the expansion and activation of memory-like NK cells, and belongs to the technical field of cell culture. The application provides a method for obtaining strong memory-like NK cells, which comprises using complete culture medium, IL-2, IL-12, IL-15, IL-18, sodium alpha-ketoglutarate and DOT1L inhibitor; the concentration of the sodium alpha-ketoglutarate is 0.1-2 mM, and the concentration of the DOT1L inhibitor is 10-100 nM. The addition of low-concentration sodium alpha-ketoglutarate in the complete culture medium of memory-like NK cells can promote the in-vivo and in-vitro proliferation capacity of the memory-like NK cells. The addition of low-concentration DOT1L inhibitor in the late culture stage can further enhance the killing function of the memory-like NK cells by inhibiting H3K79me2 / 3, etc., so that memory-like NK cells with a larger number and stronger killing capacity are obtained.

This invention discloses the application of T cells overexpressing PRDM16 in the preparation of anti-tumor or infectious disease drugs. Through experiments, this invention verifies that overexpression of PRDM16 enhances the in vivo and in vitro activity of T cells. It was found that in vitro overexpression of PRDM16 significantly enhances the killing effect of T cells on target cells. In vivo reinfusion of PRDM16 has stronger anti-tumor and anti-infection functions compared to wild-type T cells. Therefore, it can be used in malignant tumors and infectious diseases to enhance the efficacy of T cell adoptive therapy and solve the defect of T cell adoptive therapy where the killing power of target cells is suppressed due to environmental influences.

The application discloses an integrated in-situ observation carrier table cell culture device, which comprises a surrounding containing mechanism, a cell carrier, a stress loading mechanism and a control circuit board. The application also discloses an environment control method based on the integrated in-situ observation carrier table cell culture device. The integrated in-situ observation carrier table cell culture device and the environment control method are used for cell in-vitro culture and can realize in-situ real-time microscopic observation of cells, and realize multi-stage regulation of gas and temperature in the integrated in-situ observation carrier table cell culture device. The heat distribution and the uniform distribution of gas concentration are realized through the internal mixing, internal circulation and external circulation integrated method. The application has the characteristics of high portability, high integration, convenient operation, high flexibility, low cost and multiple functions.

This invention relates to a brain-targeting nanomedicine formulation for glioblastoma and its preparation method, belonging to the field of pharmaceutical technology. The formulation comprises an active pharmaceutical ingredient, an amphiphilic block copolymer carrier, a covalently bonded brain-targeting ligand, and a stabilizer. The preparation method includes: chemically coupling the targeting ligand to the carrier material; self-assembling the drug, modified carrier, and stabilizer into nanoparticles using a nanoprecipitation method; and obtaining the final product through membrane extrusion granulation, purification, and lyophilization. The resulting nanoparticles have uniform particle size, high drug loading, and good stability, and can simultaneously achieve efficient crossing of the blood-brain barrier and specific targeting of glioma cells. In vitro and in vivo experiments show that this formulation can significantly improve drug accumulation at brain tumor sites, inhibit tumor growth, and prolong the survival of model animals. Furthermore, the preparation process is controllable and easily scaled up.

This invention relates to a bilayer composite CAR-T cell in vivo delivery scaffold and its application. The in vivo delivery scaffold comprises an inner layer and an outer layer. The inner layer comprises a methacrylated hydrogel and δ-MnO2 nanosheets and cytokine 1 linked thereto. The outer layer comprises a composite hydrogel and cytokine 2 linked thereto. The composite hydrogel comprises hyaluronic acid and methacrylated gelatin. This bilayer scaffold achieves a synergistic system for structured immune induction and functional signal maintenance. The outer lymphoid-inducible matrix constructs a spatial framework for immune cell communication and memory formation, and delivers nutritional support to the inner layer. The inner oxygen-cytokine complex system maintains CAR-T cell activity and metabolic homeostasis. The synergy of these two layers can form a locally sustainable artificial immune microecology for immune activation and memory maintenance, providing a novel material basis for the long-term effectiveness and safety of CAR-T cell therapy in solid tumors.

This invention discloses a method for directed differentiation of natural killer (NK) cells and its application, specifically a kit comprising a first differentiation medium and a second differentiation medium. The first differentiation medium includes a basal differentiation medium containing SCF, FLT3L, IL-2, IL-3, IL-7, and IL-15. The second differentiation medium includes a basal differentiation medium containing IL-7 and IL-15. The basal differentiation medium comprises: DMEM / F-12 medium, DMEM medium, human AB serum, L-glutamine, 2-mercaptoethanol, sodium selenite, ethanolamine, and L-ascorbic acid. The method for directed differentiation of NK cells and the corresponding kit provided by this invention achieve a breakthrough in the in vitro differentiation paradigm of NK cells through innovative mechanisms of synergistic regulation by multiple transcription factors and temporal stimulation by cytokines.

The application discloses application of MST1 interfering RNA in promoting in-vitro differentiation of ESCs into insulin-secreting cells, and belongs to the technical field of biotechnology. In the process of in-vitro directional differentiation of rat ESCs into beta cells, the application infects by using an MST1 shRNA lentivirus vector, and indexes are detected and functions are determined by using cell biology and molecular biology methods, and it is found for the first time that the efficiency of inducing ESCs to differentiate into beta cell-like cells can be improved by reducing the expression of MST1. Meanwhile, how MST1 realizes the regulation of beta cell maturation by means of PDX1 in the process of directional differentiation of rat ESCs into beta cells is described, the reason affecting in-vitro maturation of beta cells is discussed, and thus the system of directional differentiation of ESCs into mature beta cells is optimized, which has important significance for obtaining beta cells with normal insulin secretion function in-vitro.

The present application belongs to the technical field of pharmaceutical preparation and use, and particularly relates to a composition of isofraxidin and application thereof in preparation of a medicine for treating thyroid cancer. The present application explores the role of isofraxidin in treating anaplastic thyroid cancer, and fully proves that isofraxidin can significantly inhibit the proliferation of anaplastic thyroid cancer cells, induce the apoptosis of anaplastic thyroid cancer cells, up-regulate the expression of apoptosis-related proteins cleaved-caspase3 and cleaved-PARP of anaplastic thyroid cancer cells, and inhibit the migration of anaplastic thyroid cancer cells by using a model of cell line xenograft tumor nude mice and cell in-vitro and in-vivo combination.

The application provides an enhancer for enhancing CAR-T cell expansion and memory phenotype maintenance and an application thereof, relates to the technical field of biological medicine, and adds a small molecule compound IWR-1-endo to the activation of T cells, virus transduction and / or a culture system in a subsequent expansion culture stage, so that the in-vitro expansion efficiency of CAR-T cells can be significantly improved, a larger number of effector cells can be obtained in the same culture time, T cells are effectively inhibited to differentiate into terminal effector cells, the development of the T cells to CAR-Tscm cells and CAR-Tcm subgroups with long-term activity and memory potential is guided and maintained, the product quality is improved, the specific killing capacity on target tumor cells is higher in-vitro, tumors are more effectively removed and long-term control is achieved in an animal model, stronger in-vivo persistence and anti-tumor efficacy are shown. A new strategy for efficiently expanding CAR-T cells in-vitro is provided.

The application belongs to the technical field of tumor immunotherapy, and particularly relates to an anti-mesothelin antibody and application thereof, and the application finds three mouse-derived antibodies with high affinity, and the antibodies are subjected to humanization treatment; the affinity is significantly higher than that of SS1 antibody. On this basis, a second-generation CAR-T cell based on the above antibody is constructed, and the in-vitro killing effect is better than that of a conventional SS1 CAR-T, and the CAR-T cell in a humanized form has tumor cell killing capacity equivalent to that of a mouse-derived CAR-T cell, and the cell exhaustion level is significantly reduced within a long time of 0-14 days after being stimulated by an antigen. The chimeric antigen receptor T cell has strong killing activity on mesothelin-positive tumor cells, uses a fully human antibody as an scfv, has no immunogenicity, can be repeatedly administered, and enhances the treatment effect of the CAR-T cell.